NEW research has revealed that sodium-glucose cotransporter 2 inhibitors (SGLT2is) are associated with an 18% reduction in ...

Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% ...

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Insmed (INSM – Research Report), with a price ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023- -NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Patients with and without obesity who also have type 2 diabetes and are taking GLP-1 RAs have a decreased risk for pancreatic cancer.

Semaglutide, the active ingredient in Ozempic and Wegovy, may also help lower the risk of developing Alzheimer’s disease in people living with type 2 diabetes.

People with type 2 diabetes who use semaglutide drugs like Ozempic and Wegovy appear to have a lower risk of Alzheimer's ...

they identified 16,058 patients with MASLD and type 2 diabetes who initiated a GLP-1 RA between 2006 and 2022 and an equal number of propensity score–matched patients who initiated a dipeptidyl ...

Type 2 diabetes occurs when the body does not make enough insulin or use it correctly. Some people require insulin or other medication, while others can manage blood sugar levels through diet and ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...